Skip to main content
Clinical Trials/NCT01283074
NCT01283074
Completed
N/A

Prognostic Factors of Long-term Response to Treatment With Pegylated Interferon Alfa-2a in Patients With HbeAg-negative Chronic Hepatitis B. (Perseas)

Hoffmann-La Roche0 sites107 target enrollmentMay 2009

Overview

Phase
N/A
Intervention
Not specified
Conditions
Hepatitis B, Chronic
Sponsor
Hoffmann-La Roche
Enrollment
107
Primary Endpoint
Percentage of patients with combined (virological and biochemical) response
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

This observational, multi-center, open-label study will evaluate the prognostic factors of long-term-response and the safety of Pegasys (peginterferon alfa-2a) in patients with HbeAg-negative chronic hepatitis B. Data will be collected for 96 weeks.

Registry
clinicaltrials.gov
Start Date
May 2009
End Date
November 2012
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult patients, \>/=18 years of age
  • Diagnosis of HBeAg-negative chronic hepatitis B with compensated hepatic disease, virus multiplication, raised alanine amino transferase results and/or fibrosis

Exclusion Criteria

  • Co-infection with hepatitis A, C or D
  • Co-infection with human immunodeficiency virus (HIV)
  • Severe hepatic dysfunction or decompensated liver disease

Outcomes

Primary Outcomes

Percentage of patients with combined (virological and biochemical) response

Time Frame: 48 weeks after end of treatment

Secondary Outcomes

  • Normalization of serum alanine aminotransferase(12 months)
  • Safety (Incidence of adverse events)(12 months)

Similar Trials